Skip to main content

RedHill Biopharma Ltd.

corporate_fare Company Profile

RedHill Biopharma Ltd.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed RDHL - Latest Insights

RDHL
Apr 27, 2026, 8:18 AM EDT
Filing Type: 20-F
Importance Score:
9
RDHL
Apr 27, 2026, 8:04 AM EDT
Filing Type: 6-K
Importance Score:
9
RDHL
Apr 27, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
RDHL
Apr 22, 2026, 8:02 AM EDT
Filing Type: 6-K
Importance Score:
7
RDHL
Apr 14, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
9
RDHL
Feb 25, 2026, 7:01 AM EST
Filing Type: 6-K
Importance Score:
8
RDHL
Feb 02, 2026, 7:00 AM EST
Filing Type: 424B3
Importance Score:
9
RDHL
Jan 27, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
9
RDHL
Jan 22, 2026, 4:04 PM EST
Filing Type: F-1/A
Importance Score:
9
RDHL
Jan 22, 2026, 8:56 AM EST
Filing Type: 6-K
Importance Score:
8
RDHL
Jan 05, 2026, 7:02 AM EST
Filing Type: 6-K
Importance Score:
8